Antimalarial Drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells

Chronic lymphocytic leukemia (CLL) is the most common leukemia and is characterized by the accumulation of monoclonal B cells with typical immunophenotype in peripheral blood, marrow, lymph nodes, and spleen [1]. Patient outcomes are heterogeneous with unmutated status of the immunoglobulin heavy chain variable region (IGHV) and TP53 disruption being important poor prognostic markers. While chemoimmunotherapy remains standard first-line treatment for most patients, the B-cell receptor pathway inhibitors, ibrutinib and idelalisib, or the bcl-2 antagonist, venetoclax, are highly effective in chemotherapy-refractory patients and for those with TP53 dysfunction [2,3].
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research